4D Molecular Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
FDMT Nasdaq 2836 www.4dmoleculartherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates - Mar 18th, 2026 3:25 pm
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones - Mar 18th, 2026 2:05 pm
4DMT to Participate in Upcoming Investor Meetings - Mar 16th, 2026 6:00 am
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference - Mar 16th, 2026 4:31 am
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk - Mar 16th, 2026 3:15 am
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street? - Feb 28th, 2026 12:21 am
4DMT to Participate in Upcoming Investor Conferences - Feb 19th, 2026 6:00 am
4DMT Announces New Employment Inducement Grants - Feb 13th, 2026 2:05 pm
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD - Feb 9th, 2026 6:00 am
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Feb 2nd, 2026 7:53 am
4DMT Provides Company Update and Anticipated Development Milestones for 2026 - Jan 7th, 2026 6:00 am
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Dec 27th, 2025 5:43 am
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Dec 23rd, 2025 4:45 am
4D Molecular Reports Positive Interim Early-Stage Data in Cystic Fibrosis Genetic Medicine Trial, Selects Mid-Stage Dose - Dec 17th, 2025 6:04 am
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease - Dec 17th, 2025 5:00 am
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference - Dec 8th, 2025 6:00 am
NovaBridge’s Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward - Nov 20th, 2025 6:00 pm
4DMT to Participate in 8th Annual Evercore Healthcare Conference - Nov 20th, 2025 6:00 am
4DMT Appoints Kristian Humer as Chief Financial Officer - Nov 17th, 2025 4:00 am
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates - Nov 10th, 2025 7:15 am